Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naive Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Trial Profile

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naive Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Primary endpoint (Time to PSA progression) has been met, according to the results presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top